You are here

Development of a clinical hemoglobin modulator

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42HL110727-02
Agency Tracking Number: R42HL110727
Amount: $999,992.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: NHLBI
Solicitation Number: PA13-235
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-09-15
Award End Date (Contract End Date): 2016-04-30
Small Business Information
45 Beaver Rd, Weston, MA, 02493-1017
DUNS: 808428689
HUBZone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: N
Principal Investigator
 SUSAN PERRINE
 (617) 638-5639
 sperrine@bu.edu
Business Contact
 DOUGLAS FALLER
Phone: (781) 929-5604
Email: dfaller@bu.edu
Research Institution
 UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
 1105 N STONEWALL AVE
OKLAHOMA CITY, OK, 73117-1221
 Nonprofit college or university
Abstract
DESCRIPTION provided by applicant The thalassemias and sickle cell disease are serious genetic blood diseases which are WHO designated as a growing global health burden The disorders decrease production or alter structure of the b chain of adult hemoglobin A and are characterized by anemia chronic organ damage and early mortality HbF is another type of normal hemoglobin which is suppressed in infancy Decades of research have shown that any incremental increase in HbF reduces the severity of sickle cell disease and the life threatening anemia of b thalassemia Pharmacologic augmentation of fetal hemoglobin g globin chain production to replace the defective or missing b globin chains is accepted as a therapeutic modality Only one therapeutic hydroxyurea is approved for sickle cell disease and no definitive therapeutic agent is approved for beta thalassemia Additional HbF inducing therapies are needed We utilized a novel high throughput screening program to interrogate a library of drugs which are already EMEA or FDA approved for other medical conditions and identified a panel of previously unrecognized potent HbF inducing drugs HbF inducing activity was validated in a secondary reporter assays in patientsandapos erythroid progenitors and lead therapeutics were evaluated in baboons on our Phase I STTR grant This primate model has been predictive of subsequent human responses for other drugs One therapeutic Benserazide was particularly intriguing in inducing high level fetal globin by fold over baseline with brif treatment in the baboon We found the drug suppresses two components of a major repressor complex of the fetal hemoglobin gene The drug has been used for decades in Europe and Canada as a PK enhancer of levodopa for treatment of Parkinsonandapos s disease and has a benign safety profile Accordingly we propose to repurpose Benserazide for treatment the beta hemoglobinopathies Our Aims include Aim I Determine an optimal dosing regimen of Benserazide for inducing sustained HbF in vivo in anemic nonhuman primates Aim II Produce a formulation suitable for a dose ranging trial in hemoglobinopathy patients Aim III Obtain a US IND to evaluate the EU approved therapeutic in patients with sickle cell disease and beta thalassemiaPUBLIC HEALTH RELEVANCE This proposal will repurpose a therapeutic which is currently approved in Canada and the EU in a combination tablet for another condition for treatment of serious blood diseases sickle cell disease and beta thalassemia a WHO designated global health burden Dose and regimens will be optimized in a nonhuman primate model a clinical protocol will be designed drug formulated and a US IND obtained This work will enable a Canadian and EU approved therapeutic to enter clinical trials in patients with beta hemoglobinopathies

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government